Table 3 Study group characteristics – treatment and course of hospitalization.
Whole group (n = 4071) | Females | Males | P value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
All (n = 1888) | Survivors (n = 1739) | Nonsurvivors (n = 149) | P value | All (n = 2183) | Survivors (n = 1996) | Nonsurvivors (n = 187) | P value | Females vs. Males | ||
ACEI or ARB, n (%) | 903 (22.2%) | 409 (21.7%) | 349 (20.9%) | 60 (27.8%) | 0.02 | 494 (22.6%) | 413 (21.7%) | 81 (29.1%) | 0.006 | 0.46 |
Statin, n (%) | 616 (15.1%) | 264 (14.0%) | 209 (12.5%) | 55 (25.5%) | < 0.001 | 352 (16.1%) | 279 (14.7%) | 73 (26.3%) | < 0.001 | 0.06 |
Beta-blocker, n (%) | 1249 (30.7%) | 580 (30.7%) | 464 (27.8%) | 116 (53.7%) | < 0.001 | 669 (30.7%) | 535 (28.1%) | 134 (48.2%) | < 0.001 | 0.96 |
Dexamethasone, n (%) | 1067 (26.2%) | 446 (23.6%) | 388 (23.2%) | 58 (26.9%) | 0.24 | 621 (28.5%) | 540 (28.4%) | 81 (29.1%) | 0.76 | < 0.001 |
Sympathomimetic amines, n (%) | 165 (4.1%) | 72 (3.8%) | 64 (3.8%) | 8 (3.7%) | 0.93 | 93 (3.8%) | 71 (3.7%) | 22 (7.9%) | 0.001 | 0.47 |
Mechanical ventilation, n (%) | 186 (4.6%) | 82 (4.3%) | 76 (4.6%) | 6 (2.8%) | 0.23 | 104 (4.8%) | 90 (4.7%) | 14 (5.0%) | 0.82 | 0.52 |
Therapy on ICU, n (%) | 206 (5.1%) | 86 (4.6%) | 77 (4.6%) | 9 (4.2%) | 0.77 | 120 (5.5%) | 101 (5.3%) | 19 (6.8%) | 0.29 | 0.17 |
Noninvasive oxygen therapy, n (%) | 332 (8.2%) | 113 (6.0%) | 108 (6.5%) | 5 (2.3%) | 0.02 | 219 (10.0%) | 201 (10.6%) | 18 (6.5%) | 0.04 | < 0.001 |
Dialysis, n (%) | 123 (3.0%) | 44 (2.3%) | 28 (1.7%) | 16 (7.4%) | < 0.001 | 79 (3.6%) | 56 (2.9%) | 23 (8.3%) | < 0.001 | 0.017 |
Length of hospitalization (days) | 17.7 (12.6) | 14.0 (9.0–21.0) | 13.0 (9.0–20.0) | 20.0 (14.0–34.0) | < 0.001 | 14.0 (10.0–22.0) | 14.0 (10.0–21.0) | 21.0 (13.0–35.0) | < 0.001 | 0.003 |
Length of stay on ICU (days) | 22.1 (18.6) | 13.5 (8.0–29.0) | 14.0 (9.0–27.0) | 12.0 (8.0–40.0) | 0.88 | 17.5 (8.5–36.0) | 17.0 (8.0–32.0) | 18.0 (9.0–49.0) | 0.32 | 0.34 |
